Monograph Details
|
|
Gastrointestinal Tract
> Hyperacidity, GERD, and ulcers
|
|
BIAXIN |
| Manufacturer |
|
Abbott Laboratories |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Macrolide. |
| Generic Name |
|
Clarithromycin 250mg, 500mg; tabs. |
| Indications |
|
Triple therapy (w. amoxicillin + lansoprazole or omeprazole) for treating patients with H. pylori infection and duodenal ulcer disease. Dual therapy (w. omeprazole) for treating active duodenal ulcer associated with H. pylori infection. |
| Children |
|
Not recommended. |
| Adults |
|
Triple therapy: clarithromycin 500mg + lansoprazole 30mg + amoxicillin 1g, all every 12 hours for 10 or 14 days. Or, clarithromycin 500mg + omeprazole 20mg + amoxicillin 1g, all every 12 hours for 10 days; may continue omeprazole for days 11–28 if ulcer was present at start. Dual therapy: clarithromycin 500mg 3 times daily + omeprazole 40mg once daily in the AM on days 1–14, then omeprazole 20mg once daily in the AM on days 15–28. CrCl <30mL/min: reduce clarithromycin dose by ½ or double dosing interval. |
| Contraindications |
|
Concomitant cisapride, pimozide. |
| Precautions |
|
Severe renal impairment. Pregnancy (Cat.C): usually not recommended. Nursing mothers. |
| Interactions |
|
See Contraindications. May potentiate theophylline, carbamazepine, omeprazole, phenytoin, digoxin, warfarin, ergot alkaloids, triazolam, cyclosporine, hexobarbital, tacrolimus, alfentanil, disopyramide, bromocriptine, valproate, rifabutin, statins; monitor these and other drugs metabolized by CYP450. May affect zidovudine levels. With ritonavir in renal impairment: reduce clarithromycin dose (see literature). |
| Adverse Reactions |
|
GI upset, abnormal taste, headache, rash, increased BUN. |
| Extra Text |
|
Note: See Prilosec entry for more information on omeprazole. See Prevacid entry for more information on lansoprazole. See Amoxil or Trimox entry for more information on amoxicillin. |
| How Supplied |
|
Tabs—60 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
